Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 16/20 | 1.00 |
| ▸ | SOAT1 | P35610 | 11/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411603 | 1.00 | DGAT1 (1.00) | DGAT1SOAT1EPHX2GSK3BDGAT2 | |
| SCHEMBL3410086 | 1.00 | DGAT1 (1.00) | DGAT1SOAT1EPHX2GSK3BDGAT2 | |
| SCHEMBL3413078 | 0.90 | DGAT1 (0.82) | DGAT1SOAT1DGAT2 | |
| SCHEMBL3413632 | 0.90 | DGAT1 (0.82) | DGAT1SOAT1DGAT2 | |
| SCHEMBL3413071 | 0.90 | DGAT1 (0.82) | DGAT1SOAT1DGAT2 | |
| Bicarbonate SCHEMBL3410090 | 0.90 | DGAT1 (0.81) | DGAT1SOAT1EPHX2GSK3BDGAT2 | |
| SCHEMBL3410917 | 0.88 | DGAT1 (1.00) | DGAT1SOAT1EPHX2DGAT2 | |
| SCHEMBL3411044 | 0.88 | DGAT1 (1.00) | DGAT1SOAT1EPHX2DGAT2 | |
| SCHEMBL3413667 | 0.88 | DGAT1 (1.00) | DGAT1SOAT1EPHX2DGAT2 | |
| SCHEMBL3413120 | 0.86 | DGAT1 (0.75) | DGAT1SOAT1DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084478-B2 | Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase | ASSTRAZENECA AB (SE) | 2011-12-27 | — | — | US | claimed |
| EP-2041100-B1 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZ0L-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE | ASTRAZENECA AB (SE) | 2010-12-22 | — | — | EP | claimed |
| US-20090275620-A1 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZOL-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | claimed |
| US-8084478-B2 | Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase | ASSTRAZENECA AB (SE) | 2011-12-27 | — | — | US | disclosed |
| EP-2041100-B1 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZ0L-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE | ASTRAZENECA AB (SE) | 2010-12-22 | — | — | EP | disclosed |
| US-20090275620-A1 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZOL-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275620-A1 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZOL-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE | ACAT2, ACAT1, DGAT1 | DGAT1 3/4885SOAT1 11/4885EPHX2 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.